I found the field of Pharmacology & Pharmacy very interesting. Saw the article Design and synthesis of new norfloxacin-1,3,4-oxadiazole hybrids as antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA) published in 2019. SDS of cas: 50-84-0, Reprint Addresses Guo, Y; Yang, RG; Qin, SS (corresponding author), Zhengzhou Univ, Sch Pharmaceut Sci, Minist Educ, Key Lab Adv Drug Preparat Technol, 100 KeXue Ave, Zhengzhou 450001, Henan, Peoples R China.. The CAS is 50-84-0. Through research, I have a further understanding and discovery of 2,4-Dichlorobenzoic acid
Toward the search of new antibacterial agents to control methicillin-resistant Staphylococcus aureus (MRSA), a class of new norfloxacin-1,3,4-oxadiazole hybrids were designed and synthesized. Antibacterial activities against drug-sensitive bacteria S. aureus and clinical drug resistant isolates of MRSA were evaluated. Compound 5k exhibited excellent antibacterial activities against S. aureus (MIC: 2 mu g/mL) and MRSA1-3 (MIC: 0.25-1 mu g/mL). The time-kill kinetics demonstrated that compound 5k had an advantage over commonly used antibiotics vancomycin in killing S. aureus and MRSA. Moreover, compound 5k could inhibit the bacteria and destroy their membranes in a short time, and showed very low cytotoxicity to NRK-52E cells. Some interesting structure-activity relationships (SARs) were also discussed. These results indicated that these norfloxacin-1,3,4-oxadiazole hybrids could be further developed into new antibacterial agents against MRSA.
SDS of cas: 50-84-0. Welcome to talk about 50-84-0, If you have any questions, you can contact Guo, Y; Xu, T; Bao, CN; Liu, ZY; Fan, JP; Yang, RG; Qin, SS or send Email.
Reference:
Chloride – Wikipedia,
,Chlorides – an overview | ScienceDirect Topics